内分泌联合唑来膦酸治疗晚期前列腺癌临床对照研究  

Controlled study on endocrine therapy combined with zoledronic acid treatment of advanced prostate cancer

作　　者：余绍龙[1] 黄小琴[1] 任晓艳[1] 林峰[1] 邓永榆[1] 温志鹏[1] 陈智峰[1] 王炎[1] 

机构地区：[1]深圳市中医院泌尿科,广东深圳518033

出　　处：《中国当代医药》2010年第14期36-36,39,共2页China Modern Medicine

摘　　要：目的:评价内分泌联合唑来膦酸治疗晚期前列腺癌的疗效及安全性。方法:回顾分析40例晚期前列腺癌患者,给予内分泌治疗并检测血清ALP值的临床资料。结果:与基础值相比,治疗组第3、6、9、12个月血清ALP值分别减少79.3%(P=0.017)、84.7%(P=0.015)、82.9%(P=0.017)、82.5%(P=0.020);对照组分别减少45.9%(P=0.13)、35.2%(P=0.21)、30.3%(P=0.26)、20.2%(P=0.45)。治疗组血清ALP水平显著低于对照组(P<0.01)。结论:唑来膦酸可降低合并骨转移前列腺癌患者的骨代谢水平,防治肿瘤细胞及内分泌治疗引起的骨质疏松。Objective： To evaluate the efficacy and safety of endocrine therapy combined with zoledronic acid in the treatment of advanced prostate cancer. Methods： A retrospective analysis of 40 patients with advanced prostate cancer were treated with endocrine therapy and serum ALP values. Results： Compared with baseline, after 3,6,9,12 months treatment, serum ALP values of the treatment group decreased 79.3%（P=0.017）, 84.7%（P=0.015）, 82.9%（P=0.017）, 82.5%（P=0.020）; those of the control group decreased 45.9%（P=0.13）, 35.2%（P=0.21）, 30.3%（P=0.26）, 20.2%（P=0.45）.The serum ALP level of the treatment group was significantly lower than that of the control group （P〈0.01）. Conclusion： Zoledronic acid can reduce the bone metabolism of the prostate cancer patients with bone metastasis, control the induced osteoporosis caused by tumor cells and endocrine treatment.

关 键 词：前列腺癌 唑来膦酸 内分泌治疗 

分 类 号：R737.25[医药卫生—肿瘤]